---
annotations:
- id: PW:0001025
  parent: disease pathway
  type: Pathway Ontology
  value: allograft rejection pathway
- id: PW:0000013
  parent: disease pathway
  type: Pathway Ontology
  value: disease pathway
- id: PW:0000235
  parent: regulatory pathway
  type: Pathway Ontology
  value: adaptive immune response pathway
authors:
- Nsalomonis
- MaintBot
- DMicael
- Ddigles
- Khanspers
- Mkutmon
- MirellaKalafati
- AlexanderPico
- Fehrhart
- DeSl
- Eweitz
- Susan
citedin:
- link: PMC9312476
  title: Immunomodulation of Pluripotent Stem Cell-Derived Mesenchymal Stem Cells
    in Rotator Cuff Tears Model (2022)
- link: PMC9138293
  title: 'An NF-ÎºB- and Therapy-Related Regulatory Network in Glioma: A Potential
    Mechanism of Action for Natural Antiglioma Agents (2022)'
- link: PMC8751594
  title: DNA methylation of ARHGAP30 is negatively associated with ARHGAP30 expression
    in lung adenocarcinoma, which reduces tumor immunity and is detrimental to patient
    survival (2021)
- link: PMC8083324
  title: Bioinformatics and system biology approach to identify the influences of
    SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive
    pulmonary disease patients (2021)
- link: PMC7702209
  title: LMWF5A suppresses cytokine release by modulating select inflammatory transcription
    factor activity in stimulated PBMC (2020)
- link: PMC7339012
  title: Hematopoietic stem-cell senescence and myocardial repair - Coronary artery
    disease genotype/phenotype analysis of post-MI myocardial regeneration response
    induced by CABG/CD133+ bone marrow hematopoietic stem cell treatment in RCT PERFECT
    Phase 3 (2020)
description: This pathway illustrates molecular interactions involved in the fundamental
  adaptive immune response for allograft destruction. This pathway was adapted in
  large part from [http://www.genome.jp/kegg/pathway/hsa/hsa05330.html KEGG]. In the
  initial step of this diagram, antigen presenting cells (APC's), either those from
  the donor (direct pathway) or from the recipient (indirect pathway) activate naive
  t cells leading to both CD8+ and CD4+ T cell maturation. CD8+ stimulated T cells
  lead to apoptosis of the allograft donor cells whereas CD4+ T cells differentiate
  into TH1, TH2, T17, and Treg cells. Activated TH1 produces TNFA and NO and damages
  donor graft cells by cytotoxicity. TH2 cell activates B cells. Activated B cells
  lead to plasma cell formation followed by IgG antibodies and the complement cascade
  pathway in acute antibody-mediated rejection (AMR) and chronic AMR with C3 being
  the therapeutic target. Exogenous treatment with YCF inhibits C3, thus preventing
  AMR. Eculizumab binds to C5 which prevent C5a production and the membrane attack
  complex.  C3a and C35 act as potent chemotactic factors, promoting the infiltration
  of pro-inflammatory cells. Belatacept inhibits CD80/86 binding to CD28. Corticosteroids
  inhibit pro-inflammatory cytokines. Corticosteroids contribute to immune suppression
  such as CTLA4 which inhibits T-cell activation.   Proteins on this pathway have
  targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP2328
  CPTAC Assay Portal]
last-edited: 2022-01-11
ndex: 4af9fe3e-8b64-11eb-9e72-0ac135e8bacf
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP2328
- /instance/WP2328
- /instance/WP2328_r120805
revision: r120805
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP2328.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: This pathway illustrates molecular interactions involved in the fundamental
    adaptive immune response for allograft destruction. This pathway was adapted in
    large part from [http://www.genome.jp/kegg/pathway/hsa/hsa05330.html KEGG]. In
    the initial step of this diagram, antigen presenting cells (APC's), either those
    from the donor (direct pathway) or from the recipient (indirect pathway) activate
    naive t cells leading to both CD8+ and CD4+ T cell maturation. CD8+ stimulated
    T cells lead to apoptosis of the allograft donor cells whereas CD4+ T cells differentiate
    into TH1, TH2, T17, and Treg cells. Activated TH1 produces TNFA and NO and damages
    donor graft cells by cytotoxicity. TH2 cell activates B cells. Activated B cells
    lead to plasma cell formation followed by IgG antibodies and the complement cascade
    pathway in acute antibody-mediated rejection (AMR) and chronic AMR with C3 being
    the therapeutic target. Exogenous treatment with YCF inhibits C3, thus preventing
    AMR. Eculizumab binds to C5 which prevent C5a production and the membrane attack
    complex.  C3a and C35 act as potent chemotactic factors, promoting the infiltration
    of pro-inflammatory cells. Belatacept inhibits CD80/86 binding to CD28. Corticosteroids
    inhibit pro-inflammatory cytokines. Corticosteroids contribute to immune suppression
    such as CTLA4 which inhibits T-cell activation.   Proteins on this pathway have
    targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP2328
    CPTAC Assay Portal]
  keywords:
  - ABCB1
  - AGTR1
  - BHMT2
  - BOLA class I histocompatibility antigen
  - Basiliximab
  - Belatacept
  - C1QA
  - C1QB
  - C1QC
  - C2
  - C3
  - C4A
  - C4B
  - C5
  - C6
  - C7
  - C8A
  - C8B
  - C9
  - CASP3
  - CASP7
  - CASP8
  - CASP9
  - CCL19
  - CCL21
  - CD28
  - CD40
  - CD40LG
  - CD55
  - CD80
  - CD86
  - COL5
  - CSNK2A2
  - CTLA4
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL9
  - CXCR5
  - Cell adhesion molecules (CAMs)
  - Ciclosporin
  - Daclizumab
  - ECULIZUMAB
  - FAS
  - FASLG
  - FOXP3
  - Fenofibrate
  - GABPA
  - GDNF
  - GNLY
  - GZMB
  - HARS
  - HLA-A
  - HLA-B
  - HLA-C
  - HLA-DMA
  - HLA-DMB
  - HLA-DOA
  - HLA-DOB
  - HLA-DPA1
  - HLA-DPB1
  - HLA-DQA1
  - HLA-DQA2
  - HLA-DQB1
  - HLA-DRA
  - HLA-DRB1
  - HLA-DRB3
  - HLA-DRB4
  - HLA-DRB5
  - HLA-E
  - HLA-F
  - HLA-G
  - IFNG
  - IL10
  - IL12A
  - IL12B
  - IL13
  - IL17A
  - IL1A
  - IL1B
  - IL2
  - IL21
  - IL22
  - IL2RA
  - IL4
  - IL5
  - IL8
  - LRRK2
  - MICA
  - Methylprednisolone
  - Nitric oxide
  - PDGFRA
  - PECR
  - PRF1
  - PRKCZ
  - Prednisone
  - STAT1
  - Sirolimus
  - TGFB1
  - TNF
  - TRAV
  - TRBV
  - TUBA1B
  - Tacrolimus
  - VEGFA
  - VIM
  - immunoglobulin heavy chain
  license: CC0
  name: Allograft rejection
seo: CreativeWork
title: Allograft rejection
wpid: WP2328
---